No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation

[1]  R. Suzuki,et al.  Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  S. Parmar,et al.  Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantation , 2013, British journal of haematology.

[3]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  S. Asano,et al.  Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan , 2007, Bone Marrow Transplantation.

[5]  G. Helbig,et al.  Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies , 2007, Annals of Hematology.

[6]  K. Zhu,et al.  Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation , 2007, Hematology.

[7]  W. Siegert,et al.  After major ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B , 2005, Transfusion.

[8]  J. P. McCoy,et al.  Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation , 2005, British journal of haematology.

[9]  M. Minegishi,et al.  Fludarabine- and Cyclophosphamide-Based Nonmyeloablative Conditioning Regimen for Transplantation of Chronic Granulomatous Disease: Possible Correlation with Prolonged Pure Red Cell Aplasia , 2004, International journal of hematology.

[10]  A. Barrett,et al.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.

[11]  R. Storb,et al.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. , 2000, Blood.

[12]  D. Wernet,et al.  Isoagglutinins following ABO‐Incompatible Bone Marrow Transplantation , 1992, Vox sanguinis.

[13]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[14]  M. A. Williams,et al.  An Explanation of the Failure of the Direct Antiglobulin Test to Detect Erythrocyte Sensitization in ABO Haemolytic Disease of the Newborn and Observations on Pinocytosis of IgG Anti‐A Antibodies by Infant (Cord) Red Cells , 1971, British journal of haematology.

[15]  S. Kim,et al.  Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.

[16]  K. Neftel,et al.  Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. , 1990, Blood.